JP2024518947A - Ｄｌｌ３及びｐｄ－１を標的とする組み合わせ療法のための投与レジメン - Google Patents

Ｄｌｌ３及びｐｄ－１を標的とする組み合わせ療法のための投与レジメン Download PDF

Info

Publication number
JP2024518947A
JP2024518947A JP2023568726A JP2023568726A JP2024518947A JP 2024518947 A JP2024518947 A JP 2024518947A JP 2023568726 A JP2023568726 A JP 2023568726A JP 2023568726 A JP2023568726 A JP 2023568726A JP 2024518947 A JP2024518947 A JP 2024518947A
Authority
JP
Japan
Prior art keywords
dll3
dose
seq
administered
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518947A5 (enExample
Inventor
ノーシン ハシェミ サドラエイ，
アディティヤ シェティ，
ムクル ミノチャ，
マリー－アン ダミエッテ スミット，
ハンセン ウォン，
シッダルタ ロイチョウドリー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2024518947A publication Critical patent/JP2024518947A/ja
Publication of JP2024518947A5 publication Critical patent/JP2024518947A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023568726A 2021-05-10 2022-05-06 Ｄｌｌ３及びｐｄ－１を標的とする組み合わせ療法のための投与レジメン Pending JP2024518947A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163186569P 2021-05-10 2021-05-10
US63/186,569 2021-05-10
PCT/US2022/028135 WO2022240688A1 (en) 2021-05-10 2022-05-06 Dosing regimen for combination therapy targeting dll3 and pd-1

Publications (2)

Publication Number Publication Date
JP2024518947A true JP2024518947A (ja) 2024-05-08
JP2024518947A5 JP2024518947A5 (enExample) 2025-05-21

Family

ID=84029376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568726A Pending JP2024518947A (ja) 2021-05-10 2022-05-06 Ｄｌｌ３及びｐｄ－１を標的とする組み合わせ療法のための投与レジメン

Country Status (12)

Country Link
US (1) US20240317856A1 (enExample)
EP (1) EP4337252A4 (enExample)
JP (1) JP2024518947A (enExample)
KR (1) KR20240006585A (enExample)
CN (1) CN117377488A (enExample)
AU (1) AU2022273509A1 (enExample)
CA (1) CA3217141A1 (enExample)
CL (1) CL2023003357A1 (enExample)
IL (1) IL307646A (enExample)
MX (1) MX2023013227A (enExample)
TW (1) TW202309092A (enExample)
WO (1) WO2022240688A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP4482586A1 (en) * 2022-02-23 2025-01-01 Amgen Inc. Cancer treatment targeting dll3
KR20250116698A (ko) * 2022-12-08 2025-08-01 암젠 인크 Dll3-발현 암의 치료 방법
CN121620371A (zh) * 2023-05-19 2026-03-06 勃林格殷格翰国际公司 T细胞衔接蛋白在治疗癌症中的用途
CN120168667B (zh) * 2025-03-18 2026-04-14 中国科学院近代物理研究所 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527908A (ja) * 2015-07-31 2018-09-27 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｄｌｌ３及びｃｄ３に結合する二重特異性抗体構築物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
CR20200539A (es) * 2018-04-10 2021-07-01 Kite Pharma Inc Receptores quiméricos de dll3 y métodos para su uso
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527908A (ja) * 2015-07-31 2018-09-27 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｄｌｌ３及びｃｄ３に結合する二重特異性抗体構築物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN, X. ET AL.: "Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 8, no. 1, JPN6026032256, 2020, pages 000785, ISSN: 0005920243 *
OWONIKOKO, T. K. ET AL.: "Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) t", JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.38, No.15_suppl., JPN6026032255, 2020, ISSN: 0005920242 *
PRICE, T. ET AL.: "403 Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. Vol.8, Suppl.3, JPN6026032257, 2020, ISSN: 0005920244 *

Also Published As

Publication number Publication date
CN117377488A (zh) 2024-01-09
US20240317856A1 (en) 2024-09-26
MX2023013227A (es) 2024-01-29
IL307646A (en) 2023-12-01
EP4337252A1 (en) 2024-03-20
CA3217141A1 (en) 2022-11-17
AU2022273509A1 (en) 2023-10-19
KR20240006585A (ko) 2024-01-15
WO2022240688A1 (en) 2022-11-17
TW202309092A (zh) 2023-03-01
EP4337252A4 (en) 2025-04-23
CL2023003357A1 (es) 2024-06-07

Similar Documents

Publication Publication Date Title
US20240317856A1 (en) Dosing regimen for combination therapy targeting dll3 and pd-1
AU2020276242B2 (en) Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
JP7709434B2 (ja) 抗ｄｌｌ３剤の投与レジメン
JP2025508786A (ja) Ｄｌｌ３を標的とする癌治療
WO2020007368A1 (zh) 低adcc/cdc功能性单抗及其制备方法与应用
CN119095619A (zh) 抗cd19药剂的剂量方案及其用途
AU2025202735A1 (en) Compositions and methods for treating extensive stage small cell lung cancer (es-sclc)
US20240010729A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
JP2026508608A (ja) メラノーマの治療における有効性の増強のためのｐｄ－１阻害剤及びｌａｇ－３阻害剤の組み合わせ
CN118785922A (zh) 靶向dll3的癌症治疗
JP2023540490A (ja) がん患者を治療するためのｐｄ－１拮抗薬及びｖｅｇｆｒ－２拮抗薬の併用療法
EA051285B1 (ru) Схема введения доз комбинированной терапии, нацеливающейся на dll3 и pd-1
EA051880B1 (ru) Схема введения доз для средств на основе антитела к dll3
TW202602488A (zh) 治療ｄｌｌ３陽性癌症受試者中腦轉移之方法
WO2025106736A2 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
EA049485B1 (ru) Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260730